Surmodics (NASDAQ:SRDX) Downgraded by StockNews.com to Buy

Surmodics (NASDAQ:SRDX) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Wednesday.

Separately, Needham & Company LLC restated a “buy” rating and set a $47.00 price objective on shares of Surmodics in a research report on Wednesday, April 10th.

Surmodics Stock Up 6.0 %

Shares of SRDX opened at $26.92 on Wednesday. Surmodics has a one year low of $16.79 and a one year high of $39.41. The company has a market cap of $383.34 million, a P/E ratio of 70.84 and a beta of 1.01. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.84 and a quick ratio of 3.97. The firm has a 50 day simple moving average of $29.14 and a two-hundred day simple moving average of $31.79.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in SRDX. Acadian Asset Management LLC grew its stake in shares of Surmodics by 18.8% during the third quarter. Acadian Asset Management LLC now owns 354,738 shares of the company’s stock worth $11,377,000 after buying an additional 56,012 shares during the last quarter. Panagora Asset Management Inc. grew its stake in shares of Surmodics by 109.8% during the fourth quarter. Panagora Asset Management Inc. now owns 44,664 shares of the company’s stock worth $1,624,000 after buying an additional 23,379 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Surmodics by 149.2% during the third quarter. Los Angeles Capital Management LLC now owns 34,916 shares of the company’s stock worth $1,120,000 after buying an additional 20,906 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Surmodics by 2.4% during the third quarter. Vanguard Group Inc. now owns 846,164 shares of the company’s stock worth $27,153,000 after buying an additional 19,635 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Surmodics during the fourth quarter worth $504,000. 96.63% of the stock is currently owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).